A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. - García-Torralba E; Navarro Manzano E; Luengo-Gil G; De la Morena Barrio P; Chaves Benito A; Pérez-Ramos M; Álvarez-Abril B; Ivars Rubio A; García-Garre E; Ayala de la Peña F; García-Martínez E (Frontiers in oncology, 2023)